Clinical Trial Results Reveal Difference in Efficacy of Novo and Lily Weight Loss Medications

Here's a guide to help you navigate through the choices and find the cough medicine that's right for you

While the intent to protect public health is clear, the execution must be refined to avoid collateral damage to independent pharmacies.

Compounded finasteride and minoxidil solution—a combination that targets hair loss at its root (literally and figuratively).

Blame is often placed on the price of drugs themselves, there are hidden factors driving up costs that many patients aren’t aware of.

OptumRx, one of the nation’s largest pharmacy benefit managers, introduced initiatives aimed at creating an "independent Pharmacy Network"

A Women's Multivitamin, specifically formulated to support women's health with a blend of essential vitamins, minerals, and plant extracts.

Michigan Attorney General Dana Nessel recently filed a lawsuit against OptumRX and Express Scripts

Between 2010 and 2022, the number of generic manufacturers in the U.S. jumped by 74%, reflecting a growing competitive environment.

The middlemen of our healthcare system are siphoning off huge profits at the expense of local pharmacies, patients, and even employers.

CVS stock is down 19% for the year, and another 5% today alone following the announcement of the new CEO

As a pharmacy owner, I can tell you exactly why this keeps happening specifically to Walgreens.

A recent audit in Mississippi, found that PBM-affiliated pharmacies were reimbursed up to 22 times higher than independent pharmacies.

The result is that many physicians end up prescribing expensive, brand-name drugs when lower-cost generic alternatives are available.

Based on 2024 data, here are the top three industries with the most expensive family health plans:

The FDA’s reconsideration of its decision to remove tirzepatide from the drug shortage list has given patients and compounding pharmacies...

Recently, Teva Pharmaceuticals, a global drug manufacturer, agreed to a $450 million settlement with the U.S. government.

This initiative marks an important step, but copay reductions alone aren't enough to impact the true costs.

This miscalculation could result in additional federal spending of $10 billion to $20 billion in 2025 alone.

A recent survey by KFF revealed significant gaps in transparency, leaving many companies in the dark about where their money is going.